Interest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice.
- Acute myeloid leukemia
- Minimal/measurable residual disease
- Multi-parameter flow cytometry
- Next-generation sequencing
- Reverse-transcriptase-polymerase-chain reaction
ASJC Scopus subject areas
- Clinical Biochemistry